A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion

Exclusion Criteria

• •Bilateral pleural effusion or concurrent peritoneal effusion, or concurrent pericardial effusion.
• •Pleural effusion is either encapsulated or severely separated; Or merge with chylothorax; Or combined with infectious pleural effusion.
• •Known allergies to the study drug or its excipient components.
• •Have participated in other clinical trials within 28 days prior to randomization.
• •Major surgery within 28 days prior to randomization.
• •Central nervous system metastatic disease, leptomeningeal disease, or cord compression.
• •Clinical unstable or uncontrolled concomitant cardiovascular, pulmonary, hepatic, renal or seizures diseases.
• •Active infections that require systemic treatment.
• •Have a history of organ transplantation.
• •Any further condition which, in the opinion of the Investigator, the participant is not suitable in the present study.